Blog
RSS FeedPosted by Michael Wonder on 15 Aug 2018
‘I wish they approved this new leukaemia drug two years ago, then I wouldn’t have had to go through hell’
12 August 2018 - Chloe Pinder was just 23 when she was diagnosed with acute lymphoblastic leukaemia, a very rare type ...
Posted by Michael Wonder on 09 Aug 2018
NICE changes its mind on Pfizer’s Besponsa
9 August 2018 - NICE has reversed its draft decision rejecting Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults ...
Posted by Michael Wonder on 08 Aug 2018
Lenvatinib mesylate and sorafenib tosylate for the treatment of patients with differentiated thyroid cancer after the use of radioactive iodine
8 August 2018 - NICE has published evidence-based recommendations on the use of lenvatinib mesylate (Lenvima) and sorafenib tosylate (Nexavar) ...
Posted by Michael Wonder on 08 Aug 2018
NICE publishes draft guidance on new use for lenvatinib mesylate
8 August 2018 - The Department of Health and Social Care has asked NICE to produce guidance on using lenvatinib mesylate ...
Posted by Michael Wonder on 08 Aug 2018
NICE publishes final appraisal determination for Alecensa
8 August 2018 - The determination relates to the use of alectinib hydrochloride for the first-line treatment of patients with untreated ...
Posted by Michael Wonder on 26 Jul 2018
NICE backing for Keytruda in classical Hodgkin's lymphoma
26 July 2018 - NICE has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund ...
Posted by Michael Wonder on 12 Jul 2018
NICE says no to Darzalex
12 July 2018 - NICE says no to myeloma ‘game changer’. ...
Posted by Michael Wonder on 12 Jul 2018
Cancer drug for children recommended after becoming cost effective for NHS patients
12 July 2018 - Around 60% of children with high-risk neuroblastoma could be treated with dinutuximab beta. ...
Posted by Michael Wonder on 11 Jul 2018
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology
11 July 2018 - A primary outcome in oncology trials is overall survival. However, to estimate overall survival accurately requires ...
Posted by Michael Wonder on 04 Jul 2018
Two of three US pharma companies receive Independence Day treat from NICE
4 July 2018 - NICE has released its final appraisal determinations for Tesaro, Pfizer and BMS cancer medicines. ...
Posted by Michael Wonder on 03 Jul 2018
NICE says Tookad too expensive for prostate cancer
3 July 2018 - The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not ...
Posted by Michael Wonder on 28 Jun 2018
NICE backs Roche’s Alecensa
28 June 2018 - Roche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, ...
Posted by Michael Wonder on 07 Jun 2018
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer
6 June 2018 - The Institute of Cancer Research, London, has expressed disappointment that the prostate cancer drug abiraterone (Zytiga) ...
Posted by Michael Wonder on 06 Jun 2018
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer
6 June 2018 - It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely ...
Posted by Michael Wonder on 06 Jun 2018
Life-extending lung cancer drug will be more widely available on the NHS after NICE review
6 June 2018 - NICE says more people should be able to freely access pembrolizumab, known as Keytruda, after a new ...